This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Seladelpar Gilead, Sel...
Human medicines European public assessment report (EPAR): Tacforius, tacrolimus,...
Questions and answers for biological medicinal products
Human medicines European public assessment report (EPAR): Pregabalin Pfizer, pre...
Human medicines European public assessment report (EPAR): Carvykti, ciltacabtage...
Herbal medicinal product: Tribuli terrestris herbaArray, D: Draft under discussion
Herbal medicinal product: Prunus avium peduncleArray,Array, D: Draft under discu...
Veterinary medicines European public assessment report (EPAR): Poulvac Procerta ...
Veterinary medicines European public assessment report (EPAR): Icthiovac ERM, in...
List of medicinal products under additional monitoring
Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagen...
Human medicines European public assessment report (EPAR): Lyrica, pregabalin, Da...
Human medicines European public assessment report (EPAR): Kavigale, sipavibart, ...
New Approach Methodologies EU-IN Horizon Scanning Report
Annex to 24-27 February 2025 CHMP Agenda
Agenda of the CHMP meeting 24-27 February 2025
Human medicines European public assessment report (EPAR): Revinty Ellipta, fluti...
Human medicines European public assessment report (EPAR): Relvar Ellipta, flutic...
Review of transparency rules for the EU Clinical Trials Information System (CTIS)